| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259882 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 19010901 |
The anatomy of an antibody–cytotoxic drug conjugate can be divided into three general components: the antibody, the linker, and the cytotoxic drug. The efficacy of any such conjugate is dictated in part by the differential expression of the target antigen in tumor versus normal tissue. HER2 is a clinically validated target for the treatment of breast cancer. Trastuzumab and, more recently, lapatinib are approved for clinical use in women whose breast cancer overexpresses HER2. a trastuzumab conjugate, which simply uses HER2 as an address for the delivery of a potent cytotoxic agent, may offer promise as an effective therapeutic modality. |
|
3.0
ado-trastuzumab emtansine
binding